OPEN SESSION, 12-15 October 2004 PROVISIONAL TIMETABLE DAY/TIME
PRESENTER/ FIRST AUTHOR
Tuesday 12th 8.30 8.50
Opening Ceremony Sumption
9.00
De Clercq
Pg no. of abstract book
ABBREVIATED TITLE
Representatives of the Government of Greece, and the EUFMD Executive Committee The Open Session; purpose and procedures Progress report Recent findings in molecular epidemiology of FMDV
9.10
Valarcher
1
Global FMD situation in 2003 and 2004
9.40
Vosloo
2
FMD in sub-Saharan Africa
10.10
Coffee
10.40
Christensen
3
Novel type O lineage detected
10.55
Knowles
4
Identification of a ninth foot-and-mouth disease virus type O topotype
11.10
Christensen
5
High-resolution molecular analysis of the 1982-3 FMD epidemic in Denmark
11.30
Nunez
6
Genetic and antigenic analysis of Italian 1993 FMDV isolates
11.45
Haydon
7
Outstanding but tractable questions regarding the micro-evolution of FMDV
12.15
Serratosa
12.30
Lunch
14.00
Uppal
14.10
Gilbert
14.40
Perez
9
Epidemiological models for global surveillance of foot-and-mouth disease
15.00
Thurmond
11
Concepts and Considerations for Global FMD Surveillance
15.20
Coffee
15.50
Alexanderson
12
Exposure intensity and FMD transmission
16.20
Esteves
13
Natural aerosol transmission of FMD in sheep
16.35
Gloster
14
Understanding airborne transmission of FMD
16.55
Orsel
15
Effect of vaccination on transmission
17.15
Eblé
16
Quantification of experimental transmission of FMDV O Taiwan in pigs
17.35
Cox
17
Emergency FMD vaccine: effect of antigen payload
17.55
Discussion
18.10
Close
Surveillance – for what purpose and how much is enough? EFSA – statement 8
FMD in small ruminants -cause for concern FMD in Turkey and Iran - trends and relationships
Transmission -and its control
Depart for Tour of old Chania and dinner
Wednesday 13th 8.00
Wernery
18
FMD and camelids: international relevance of current research Managing Diagnostic demand
8.20
Hammond
19
8.40
Ferris
20
Prospects for improved lab diagnosis using real time RT-PCR
8.55
Reid
21
Use of automated RT-PCR to detect FMDV in milk
9.20
Brocchi
22
Validation of a SPCE, for antibodies to FMDV type Asia 1.
9.40
Grazioli
23
Mapping of neutralising sites on FMD virus type Asia 1
Johnson
24
9.15
9.55
Laboratory surge capacity - Australian approach
Discussion point
Bayesian methods and predicting FMDV infection from serologic results
10.10
Coffee
10.30
Paton
25
Phase XVIII serology exercise
11.00
Goris Nesya
26
Development of secondary standards for SPCE
11.20
Discussion
11.30
Mackay
Sero-diagnosis – improvements and standardisation
Regulatory issues affecting FMD vaccine selection and use 27
Progress and regulatory requirements for FMD vaccines within the European Union
30
